On Tuesday, Shares of Encana Corporation (USA) (NYSE:ECA), gained 0.88% to $6.89.
Strong second quarter operational performance assisted Encana deliver its seventh successive quarterly enhance in liquids volumes since launching its strategy to grow high-margin production. A focused and front-end loaded capital program has positioned the company to accelerate liquids production growth in the second half of 2015. Highlights comprise:
- liquids production of about 127,300 barrels per day (bbls/d), up 87 percent year-over-year
- over 80 percent of capital invested in the company’s four most planned assets, the Permian, Eagle Ford, Duvernay and Montney
- 59 new wells brought on production in the Eagle Ford and Permian late in the second quarter, with another 76 planned in the third quarter
- reduced Eagle Ford drilling and completion costs by $1 million per well, or 18 percent, contrast to the first quarter
- pace-setting Duvernay wells with production rates of up to 2,000 bbls/d of condensate and 11.5 million cubic feet per day (MMcf/d) of rich gas after 27 days on production
- noteworthy expansion of liquids inventory in the Montney, with higher condensate yields in Dawson South and two recent Pipestone area wells each producing over 1,000 bbls/d
Encana Corporation, together with its auxiliaries, engages in the development, exploration, production, and marketing of natural gas, oil, and natural gas liquids in Canada and the United States.
Shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), inclined 3.21% to $18.98, during its last trading session.
Aegerion Pharmaceuticals declared that Aegerion board member Sandford Drexel Smith has been designated interim Chief Executive Officer of the Company.
Marc Beer offered his resignation as CEO and member of the board, as did Craig Fraser as Chief Operating Officer, effective right away.
Mr. Smith has been designated to serve as the interim Chief Executive Officer while the Company conducts a search to identify a successor. Mr. Smith will also assume Mr. Fraser’s responsibilities on an interim basis.
David Scheer, Chairman of the Board, said, “We thank Marc Beer for his years of hard work and many contributions to the Company, counting marketing approval and overseeing the successful commercial launch of JUXTAPID(R) (lomitapide) capsules in the United States in addition to leading the Company’s acquisition and re-launch of MYALEPT(R) (metreleptin) for injection. We thank Craig for his leadership of Aegerion’s U.S. commercial organization. We wish both Marc and Craig the very best in their future endeavors.”
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States. The company’s products comprise JUXTAPID (lomitapide) capsules, an adjunct to a low-fat diet and other lipid-lowering treatments, counting low-density lipoprotein, low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol in adult patients with homozygous familial hypercholesterolemia (HoFH); and LOJUXTA (lomitapide) hard capsule used as a treatment for HoFH in adults.
Finally, Splunk Inc (NASDAQ:SPLK), ended its last trade with -1.15% loss, and closed at $69.92.
Splunk, declared .conf 2015: The 6th Annual Splunk Worldwide Users’ Conference planned for Sept. 21 – 24. Thousands of attendees together with Splunk experts are set to fill the MGM Grand in Las Vegas to hear Godfrey Sullivan, chairman and CEO, Splunk, take the stage to unveil new Splunk products and innovations. .conf2015 will also feature 165 speaking sessions, an Internet of Things pavilion featuring an innovative connected car, in addition to a Splunk Women in Technology program. Register now for .conf2015.
.conf2015 will feature more than 80 customers speakers from around the world, counting:
- Steven Carter, architect, Cisco Systems: Carter will demonstrate a system using Splunk solutions and the Cisco Open SDN Controller to actively block threats within large data flows without potential performance issues of firewalls and other devices.
- Rob Schlotman, head of design and engineering, Ernst & Young: Schlotman will explain how to get answers to critical questions throughout an entire application lifecycle process with Splunk solutions, enabling everyone from IT executives to DevOps to easily understand the state of the product service and keep it operational, in addition to key feature usage.
- Mariya Gilyadova, director, MetLife Inc.: Gilyadova will share MetLife’s journey of using Splunk solutions to take the company focus on customer centricity and turn it into a planned initiative to improve customer experience.
- Patrick Hofmann, head of IT infrastructure and deputy CIO, PostFinance: Hofmann will talk about how one of Switzerland’s largest retail banks is using Splunk solutions to connect business and IT to improve cash administration, detect fraud and enhance security.
- Keisuke Noda, data store platform administrator, Rakuten: Noda will talk about some challenging points for deploying Splunk-as-a-Service, such as best practices for managing clusters and improving operations using the Splunk API and tips for expanding the Splunk platform globally.
- David Studer, systems analyst, The Vancouver Clinic: Studer will talk about how Splunk solutions enable the clinic to achieve patient privacy monitoring for a fraction of the cost of the legacy patient monitoring platforms.
Splunk, Inc. provides software products that enable organizations to gain real-time operational intelligence in the United States and internationally. The company’s products enable users to collect, index, search, explore, monitor, and analyze data regardless of format or source users.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
